Evidence map›Paper›PMID 30926784›Full record

ReviewNature communications2019

Ligand design strategies to increase stability of gadolinium-based magnetic resonance imaging contrast agents.

Thomas J Clough, Lijun Jiang, Ka-Leung Wong, Nicholas J Long

Abstract readReview
In one paragraph

Review in Nature communications, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 88 papers.

0numbers the graph read from it
0cells of the map it votes in
88citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

88 citing papers in PubMed.

  1. Review
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. Review
  8. Tetrazine-Inorganic chemistry frontiers · 2026
    Article
  9. Article
  10. Article
  11. Article
  12. The Evaluation of (1Molecules (Basel, Switzerland) · 2025
    Article
  13. Review
  14. Article
  15. Chiral Switch of Gadopiclenol: New Standards in MRI Probes.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2025
    Article
  16. Article
  17. Review
  18. Article
  19. Article
  20. Article

28 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors.

Thomas J CloughDepartment of Chemistry, Imperial College London, Molecular Sciences Research Hub, White City Campus, Wood Lane, London, W12 0BZ, UK.
Lijun JiangDepartment of Chemistry, Imperial College London, Molecular Sciences Research Hub, White City Campus, Wood Lane, London, W12 0BZ, UK.ORCID http://orcid.org/0000-0002-6499-9760
Ka-Leung WongDepartment of Chemistry, Hong Kong Baptist University, Kowloon Tong, Hong Kong SAR, China. klwong@hkbu.edu.hk.
Nicholas J LongDepartment of Chemistry, Imperial College London, Molecular Sciences Research Hub, White City Campus, Wood Lane, London, W12 0BZ, UK. n.long@imperial.ac.uk.ORCID http://orcid.org/0000-0002-8298-938X

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Gadolinium(III) complexes have been widely utilised as magnetic resonance imaging (MRI) contrast agents for decades. In recent years however, concerns have developed about their toxicity, believed to derive from demetallation of the complexes in vivo, and the relatively large quantities of compound required for a successful scan. Recent efforts have sought to enhance the relaxivity of trivalent gadolinium complexes without sacrificing their stability. This review aims to examine the strategic design of ligands synthesised for this purpose, provide an overview of recent successes in gadolinium-based contrast agent development and assess the requirements for clinical translation.

Indexed as

Magnetic Resonance ImagingContrast MediaGadoliniumLigandsMacrocyclic CompoundsContrast MediaGadoliniumLigandsMacrocyclic Compounds

Identifiers

PMID30926784
PMCPMC6441101

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.